BUBOLight® phototherapy device for treating newborn jaundice
Official title: Use of "BUBOLight®" Device as an Innovative Phototherapy Device for the Treatment of Newborn's Jaundice. A Monocentric, Descriptive Pilot Study, for the Feasibility, Safety and Tolerance of the BUBOLight® Device
Run by University Hospital, Lille · NCT04365998 · Data updated 2026-11-12
This will try the BUBOLight® textile-based phototherapy device on newborns with jaundice who need phototherapy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | Any age to 30 Days |
| Sex | All |
| Enrollment | 15 (estimated) |
| Sponsor | University Hospital, Lille Academic / other |
| Locations | 1 site (Lille) |
| Status | Recruiting |
| Started | October 8, 2020 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | December 23, 2025 |
| Trial ID | NCT04365998 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Term or near-term newborns (>35 weeks gestation) weighing ≥2.5 kg with bilirubin levels that meet national criteria for phototherapy and judged in good clinical health are ideal candidates.
✕Probably not a fit
Newborns with hemolytic jaundice, very high bilirubin requiring exchange transfusion, prior phototherapy, fever >37.8°C, congenital porphyria, or other excluded conditions are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center interventional pilot enrolls 10 newborns who require phototherapy for neonatal jaundice and treats each infant with the BUBOLight® device for a four-hour session. Total bilirubin is measured at the start of phototherapy (H0) and again six hours later (H+6) to monitor response. The trial's primary focus is device safety and satisfaction reported by parents and the healthcare team using removable luminous textile strips with optical fibers. The study is conducted at Hop Jeanne de Flandre, CHU Lille, in collaboration with Inserm.
Why it matters
Potential benefit: If successful, BUBOLight® could offer a comfortable, easy-to-use phototherapy option that may improve parent and staff satisfaction while treating neonatal jaundice.
How similar studies have gone: Conventional phototherapy is well established and effective, but textile-based or wearable phototherapy devices like BUBOLight® are relatively novel with limited prior clinical data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * At time of birth, infant is \> 35 weeks gestation * Presence of jaundice confirmed by measurement of bilirubin (transcutaneous bilirubinometer) * Total bilirubinemia rate requiring phototherapy according to National Institute for Health and Clinical Excellence. * Weight ≥2.500kg * Judged in good health by the investigator following the clinical examination and the medical data (absence of perinatal asphyxia, antibiotic treatment, respiratory disorders) * Absence of fœto-maternal rhesus incompatibility or Kell Exclusion Criteria: * Newborn already treated with phototherapy * Febrile state with body temperature \> 37.8°C * Total bilirubinaemia level is equal or excess 100 μmol / L of the indication of phototherapy. * Patient whose jaundice is due to haemolysis, obstruction functional or anatomical. * Minor relative * Newborn requiring exchange transfusion * Newborn with congenital erythropoietic porphyria or a family history of porphyria. * Patient requiring treatment other than phototherapy
Where it's running
-
Hop Jeanne de Flandre Chu Lille
Lille, France Recruiting
Study contacts
- Principal investigator: Thameur Rakza, MD — University Hospital, Lille
- Study coordinator: Thameur Rakza, MD
- Email: thameur.rakza@chru-lille.fr
- Phone: 03 20 44 63 87
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Abdominal Massage for Newborn Jaundice
Tests whether infant abdominal massage, added to routine care, can lower bilirubin levels in healthy full-term newborns.
-
neoSCB app to screen newborns for jaundice
This project will test whether the neoSCB smartphone app can accurately detect significant jaundice in newborn babies by photographing the white part of the eye.
-
Pediatric Congenital Adrenal Hyperplasia: Long-Term Outcomes and Feelings of Regret
This study looks at adults who had classic CAH from 21-hydroxylase deficiency as children to see if early surgeries and management choices are linked to long‑term satisfaction or regret.
-
Predicting Low Cardiac Output in Children After Heart Surgery Using CO2-Derived Parameters
This study tests whether CO2-derived measures can help identify low cardiac output in children after congenital heart surgery.
-
Switching to Ofatumumab: IgG Levels in People with MS
A real-life study tests whether stopping ocrelizumab and starting ofatumumab changes IgG levels in adults with multiple sclerosis who have been on ocrelizumab for at least 18 months.
-
Identifying biomarkers for CAR-T cell therapy in cancer patients
This study looks at real-world CAR-T therapy in adults with blood cancers to see which biomarkers predict who responds or relapses.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.